Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 2
Submit an article Journal homepage
210
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Recent developments in the therapy of irritable bowel syndrome

Richard J Saad Lecturer University of Michigan Medical Center, Division of Gastroenterology, Department of Medicine, Ann Arbor, MI, USA
, MD &
William D Chey Professor of Internal Medicine, Director – GI Physiology Laboratory University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, USA +1 734 936 4775; +1 734 936 7392; [email protected]
, MD AGAF FACG FACP
Pages 117-130 | Published online: 30 Jan 2008

Bibliography

  • Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005;100(5):1174-84
  • Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
  • Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005;128(3):580-9
  • Mearin F, Baro E, Roset M, et al. Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol 2004;99(1):113-21
  • Camilleri M. Motor function in irritable bowel syndrome. Can J Gastroenterol 1999;13(Suppl A):8A-11A
  • Quigley EM. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol Clin North Am 2005;34(2):221-33, vi
  • Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001;48(1):14-9
  • Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14(2):125-32
  • Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98(5 Pt 1):1187-92
  • Nozu T, Kudaira M, Kitamori S, Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol 2006;41(3):217-22
  • Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109(1):40-52
  • Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122(7):1771-7
  • Drewes AM, Petersen P, Rossel P, et al. Sensitivity and distensibility of the rectum and sigmoid colon in patients with irritable bowel syndrome. Scand J Gastroenterol 2001;36(8):827-32
  • Lawal A, Kern M, Sidhu H, et al. Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006;130(1):26-33
  • Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999;107(5A):41S-50S
  • Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007;39(3):201-15
  • Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007;19(Suppl 2):25-31
  • Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation – and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130(1):34-43
  • Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3(4):349-57
  • Gupta V, Sheffield D, Verne GN. Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig Dis Sci 2002;47(8):1716-22
  • van Orshoven NP, Andriesse GI, van Schelven LJ, et al. Subtle involvement of the parasympathetic nervous system in patients with irritable bowel syndrome. Clin Auton Res 2006;16(1):33-9
  • Blackshaw LA, Brookes SJ, Grundy D, Schemann M. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007;19(1 Suppl):1-19
  • Bueno L, de Ponti F, Fried M, et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol Motil 2007;19(1 Suppl):89-119
  • Hobson AR, Aziz Q. Brain imaging and functional gastrointestinal disorders: has it helped our understanding? Gut 2004;53(8):1198-206
  • Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124(6):1662-71
  • Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome – a meta-analysis. Am J Gastroenterol 2006;101(8):1894-9; quiz 942
  • Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5(4):457-60
  • Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007;102(5):1064-9
  • Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44(3):400-6
  • Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47(6):804-11
  • Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126(3):693-702
  • Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52(1):91-3
  • van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100(11):2510-6
  • Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic–pituitary–gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130(2):304-11
  • Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100(2):373-82
  • Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133(1):24-33
  • Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95(12):3503-6
  • Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292(7):852-8
  • Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. Aliment Pharmacol Ther 2006;24(2):183-205
  • Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133(2):136-47
  • Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15(3):355-61
  • Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(11-12):1253-69
  • Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 2005;34(2):319-35, viii
  • Mearin F. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. Digestion 2006;73(Suppl 1):28-37
  • Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125(1):19-31
  • Abdul-Baki H, El Zahabi LMN, El Hajj II, et al. A randomized double-blind placebo-controlled trial of imipramine in patients with irritable bowel syndrome (IBS). Am J Gastroenterol 2006;101(Suppl 2):S479 (Abstract)
  • Masand PS, Gupta S, Schwartz TL, et al. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Prim Care Companion J Clin Psychiatry 2002;4(1):12-6
  • Wang WA, Qian JM, Pan GZ. Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2003;25(1):74-8
  • Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99(5):914-20
  • Masand PS, Gupta S, Schwartz TL, et al. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 2005;7(4):162-6
  • Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55(8):1095-103
  • Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1(3):211-8
  • Pharmos. Available from: URL: www.pharmoscorp.com/development/tianeptine.html
  • Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15(1):79-86
  • Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;(2)
  • Chey WD, Pare P, Viegas A, et al. Tegaserod improves multiple symptoms in women with mixed/alternating bowel habits as well as those with IBS-C. Gastroenterology 2006;130(4 Suppl 2):A-26 (Abstract)
  • Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132(1):397-414
  • Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99(11):2195-203
  • Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101(5):1069-79
  • Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102(8):1709-19
  • Song GH, Leng PH, Gwee KA, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005;54(10):1402-7
  • Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005;22(10):927-34
  • Saha L, Malhotra S, Rana S, et al. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007;41(1):29-32
  • Crowell MD, Harris LA, DiBaise JK, Olden KW. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs 2007;8(1):66-70
  • Lacy BE, Campbell Levy L. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007;41(4):345-51
  • Johanson JF, Panas R, Holland PC, Ueno R. A dose-ranging, double-blind, placebo-controlled of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS). Gastroenterology 2006;130(4 Suppl 2):A-25 (Abstract)
  • Drossman DA, Chey WD, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double-blind trials. Gastroenterology 2007;132(4 Suppl 2):P-90 (Abstract)
  • Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept 1999;81(1-3):25-39
  • Andersen V, Busciglio I, Grudell A, et al. Effects of a novel, first-in-class guanylate cyclase-c activator, linaclotide acetate (Md-1100), on gastrointestinal and colonic transit and bowel habits in patients with constipation-predominant irritable bowel syndrome (c-IBS). Gastroenterology 2007;132(4 Suppl 2):A-82 (Abstract)
  • Lembo AJ, Rosenbaum DP, Chey WD, Drossman DA. Safety and efficacy of crofelemer in patients with diarrhea predominant irritable bowel syndrome (IBS-D). Gastroenterology 2007;132(4 Suppl 2):A-141 (Abstract)
  • Quigley EM, Devane J, Young D, Butler J. A randomized, double-blind, placebo-controlled study of R-verapamil in non-constipated irritable bowel syndrome. Am J Gastroenterol 2007;102(S2):S502 (Abstract)
  • Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(2):237-46
  • Karver S, Israel RJ. Methylnaltrexone improves opioid-induced constipation and reduces laxative use in patients with advanced illness. Gastroenterology 2007;132(4 Suppl 2):A-478 (Abstract)
  • Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21-day treatment-randomized clinical trial. J Pain 2005;6(3):184-92
  • Kelleher D, Johanson J, Pobiner B, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist – a study in patients with chronic idiopathic constipation (CIC) not taking opioid medication. Am J Gastroenterol 2006;101(9):s480 (Abstract)
  • McCallum RW, Cynshi O. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007;26(1):107-16
  • Ozaki K, Sudo H, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs. Inflammopharmacology 2007;15(1):36-42
  • Sudo H, Ozaki K, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil 2007;19(4):318-26
  • Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56(6):802-8
  • Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25(11):1271-81
  • Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84
  • Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145(8):557-63
  • Salix. Available from: URL: www.salix.com/news/stories/20070905.aspx
  • O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128(3):541-51
  • Brenner DM, Moeller M, Chey WD, Schoenfeld P. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2007;102(Suppl 2):S500 (Abstract)
  • Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(7):1581-90
  • Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003;18(1):77-84
  • Stefanini GF, Saggioro A, Alvisi V, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995;30(6):535-41
  • Lunardi C, Bambara LM, Biasi D, et al. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy 1991;21(5):569-72
  • Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2(10):895-904
  • Astellas. Available from: URL: www.astellas.com/global/ir/library/pdf/rd2006_1_eg.pdf
  • Theravance. Available from: URL: ir.theravance.com/ReleaseDetail.cfm?ReleaseID=250925
  • Dynogen. Available from: URL: www.dynogen.com/pipeline_gi.htm
  • Tache Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci 1993;697:233-43
  • Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42(6):845-9
  • Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53(7):958-64
  • Lecci A, Valenti C, Maggi CA. Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs 2002;3(4):589-601
  • Tousignant-Laflamme Y, Goffaux P, Bourgault P, Marchand S. Different autonomic responses to experimental pain in IBS patients and healthy controls. J Clin Gastroenterol 2006;40(9):814-20
  • Ng C, Malcolm A, Hansen R, Kellow J. Feeding and colonic distension provoke altered autonomic responses in irritable bowel syndrome. Scand J Gastroenterol 2007;42(4):441-6
  • Robert JJ, Elsenbruch S, Orr WC. Sleep-related autonomic disturbances in symptom subgroups of women with irritable bowel syndrome. Dig Dis Sci 2006;51(12):2121-7
  • Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003;1(2):111-21
  • Allergan. Available from: URL: www.allerganclinicaltrials.com/ongoing/stomach_intestine_conditions.htm
  • Quigley EM, Devane J, Young D, Butler J. A randomized, controlled, double-blind trial of s-pindolol in irritable bowel syndrome (IBS). Am J Gastroenterol 2007;102(S2):S501 (Abstract)
  • Leventer S, Kucharik R, Keogh JC, et al. The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol 2004;99(s10):s279 (Abstract)
  • Leventer S, Raudibaugh K, Frissora C, et al. The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology 2005;128(4 Suppl 2):A-94 (Abstract)
  • Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105(6):1805-15
  • Diop L, Raymond F, Fargeau H, et al. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002;302(3):1013-22
  • Eutamene H, Coelho AM, Theodorou V, et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther 2000;295(1):162-7
  • Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56(9):1218-25
  • Chugai. Available from: URL: www.chugai-pharm.co.jp/pdf/pipeline/english/070731ePipeline.pdf
  • Clinical trials. Available from: URL: clinicaltrials.gov/ct/show/NCT00401258?order=1
  • Bristol-Myers Squibb. Available from: URL: ctr.bms.com/ctd/InitTrialDetailAction.do?pnum=CN148-013%20ST
  • GlaxoSmithKline. Available from: URL: www.gsk.com/investors/pp_pipeline_standard.htm
  • Gastrotech. Available from: URL: www.gastrotechpharma.com/Product_PipeLine.htm
  • Avera. Available from: URL: www.averapharm.com/AV608.html
  • Sanofi aventis Available from: URL: en.sanofi-aventis.com/rd/portfolio/p_rd_portfolio_snc.asp

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.